1. Home
  2. Analysis
  3. Deflazacort
  4. Meropenem

Deflazacort and Meropenem drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Deflazacort (deflazacort) and Meropenem (meropenem). Common drug interactions include drug ineffective among females and pneumonia among males.

The phase IV clinical study analyzes what interactions people have when they take Deflazacort and Meropenem. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Deflazacort?

Deflazacort has active ingredients of deflazacort. eHealthMe is studying from 1,457 Deflazacort users. Check the latest studies of Deflazacort.

What is Meropenem?

Meropenem has active ingredients of meropenem. eHealthMe is studying from 33,295 Meropenem users. Check the latest studies of Meropenem.

On Jul, 13, 2026

15 people who take Deflazacort and Meropenem together, and have interactions are studied.

Deflazacort and Meropenem drug interactions.

What are the common drug interactions of Deflazacort and Meropenem, by gender? *:

female:

  1. Drug ineffective
  2. Pulmonary embolism (blockage of the main artery of the lung)
  3. Diarrhoea
  4. Colitis (inflammation of colon)
  5. Rectal haemorrhage (bleeding from anus)
  6. Arthralgia (joint pain)

male:

  1. Pneumonia
  2. Asthenia (weakness)
  3. Pain
  4. Pulmonary embolism (blockage of the main artery of the lung)
  5. Respiratory failure (inadequate gas exchange by the respiratory system)
  6. Respiratory tract infection

What are the common drug interactions of Deflazacort and Meropenem, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Drug ineffective
  2. Pulmonary embolism (blockage of the main artery of the lung)
  3. Arthralgia (joint pain)

40-49:

n/a

50-59:

n/a

60+:

  1. Diarrhoea
  2. Colitis (inflammation of colon)
  3. Rectal haemorrhage (bleeding from anus)
  4. Pneumonia
  5. Asthenia (weakness)
  6. Pain
  7. Pulmonary embolism (blockage of the main artery of the lung)
  8. Respiratory failure (inadequate gas exchange by the respiratory system)
  9. Respiratory tract infection

What are the existing conditions these people have? *

  1. Breast Cancer: 12 people, 80.00%
  2. Pain: 6 people, 40.00%
  3. Nausea (feeling of having an urge to vomit): 6 people, 40.00%
  4. Respiratory Tract Infection: 1 person, 6.67%
  5. Pulmonary Embolism (blockage of the main artery of the lung): 1 person, 6.67%
  6. Otitis Media (inflammation of the middle ear): 1 person, 6.67%
  7. Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 1 person, 6.67%
  8. Hyperlipidaemia (presence of excess lipids in the blood): 1 person, 6.67%
  9. Fever: 1 person, 6.67%
  10. Diarrhea: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Deflazacort and Meropenem?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Deflazacort and Meropenem:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Deflazacort:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Meropenem:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Deflazacort and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Meropenem and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on deflazacort and meropenem (the active ingredients of Deflazacort and Meropenem, respectively), and Deflazacort and Meropenem (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.